Mifamurtide

Mifamurtide is a synthetic analog of muramyl dipeptide, used as an immunomodulatory agent in liposomal form. It is approved for adjuvant treatment of osteosarcoma, stimulating the immune system to target cancer cells.

In the literature, Mifamurtide appears most often in work focused on cancer research, immune support and bone health. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.

Mifamurtide is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.